Vertex Pharmaceuticals’ (VRTX) Outperform Rating Reiterated at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...
The Telegraph1d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
Non-opioid pain medication OK’d by FDA; Journavx could help blunt fentanyl addiction
Almost 1,200 people in Kern County have died from fentanyl overdoses since 2018, including 171 in 2024 and an all-time high of 294 the year before, according to updated numbers from the Kern ...
Biotech Market to Grow by USD 805.6 Billion (2025-2029), Boosted by Vendor Innovation, with AI Driving Market Transformation - Technavio
Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Colombia's president calls for migrants to leave jobs in the US and return home
Colombia's president is calling on his compatriots working without legal status in the United States to leave their jobs and return home as soon as possible. “Wealth is only produced by the working ...
Forbes Daily: DeepSeek’s AI Model Raises National Security Concerns
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Black boxes found from crashed jet and FDA approves a new nonopioid painkiller: Morning Rundown
The FDA approves a new type of nonopioid painkiller for acute pain. And NBC News speaks to transgender service members who ...
PharmiWeb1d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...